328 related articles for article (PubMed ID: 30621318)
1. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets.
Alazard-Dany N; Denolly S; Boson B; Cosset FL
Viruses; 2019 Jan; 11(1):. PubMed ID: 30621318
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
3. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.
Lohmann V
Med Microbiol Immunol; 2019 Feb; 208(1):3-24. PubMed ID: 30298360
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C treatment: an incipient therapeutic revolution.
deLemos AS; Chung RT
Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
[TBL] [Abstract][Full Text] [Related]
7. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
Vachon ML; Dieterich DT
Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
[TBL] [Abstract][Full Text] [Related]
8. Chemical genetics-based development of small molecules targeting hepatitis C virus.
Jin G; Lee J; Lee K
Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
[TBL] [Abstract][Full Text] [Related]
9. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.
Spengler U
Pharmacol Ther; 2018 Mar; 183():118-126. PubMed ID: 29024739
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus-specific directly acting antiviral drugs.
Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
12. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
[TBL] [Abstract][Full Text] [Related]
14. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
[TBL] [Abstract][Full Text] [Related]
15. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
16. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting and host-targeting HCV inhibitors: current and future directions.
Chatel-Chaix L; Germain MA; Götte M; Lamarre D
Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of new investigational hepatitis C virus translation inhibitors.
Borgia G; Maraolo AE; Buonomo AR; Scotto R; Gentile I
Expert Opin Investig Drugs; 2016 Oct; 25(10):1209-14. PubMed ID: 27537604
[TBL] [Abstract][Full Text] [Related]
19. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
20. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Pár A
Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
